The CMS updated its interactive Medicare drug price tracking tool, including some information on manufacturer rebates, and released another online tool with data on drugs purchased under Medicaid. The Medicaid dashboard shows a spending increase of 300% or more on at least six drugs, including Valeant’s Ativan, or lorazepam.